Processing

Please wait...

Settings

Settings

Goto Application

1. WO2010086197 - LOW MOLECULAR WEIGHT SULPHATED POLYSACCHARIDES AS CANDIDATES FOR ANTI-ANGIOGENIC THERAPY

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

CLAIMS

1. Low molecular weight sulphated L-fucose polysaccharide fraction having: a molecular weight ranging from 11 to 30 kDa when measured with TEST A, a sulphate content ranging from 10 and 50% w/w relative to the total weight of the fraction, - a fucosis content ranging from 30 and 70% w/w relative to the total weight of the fraction, and a polydispersity index ranging from 1 and 2 wherein the fraction is obtainable by free radical depolymerisation of a crude fucan of vegetal origin.

2. A fraction according to claim 1, wherein the crude fucan is of algal origin.

3. Process for preparation of a fraction according to anyone of claims 1 or 2, comprising performing a free radical depolymerisation of crude fucans of vegetal origin, followed by a reduction.

4. Medicament comprising, as an active principle, a low molecular weight sulphated L-fucose polysaccharide fraction according to anyone of claims 1 or 2.

5. Pharmaceutical composition comprising a low molecular weight sulphated L-fucose polysaccharide fraction according to anyone of claims 1 or 2, in association with a pharmaceutically suitable vehicle.

6. Medicament or pharmaceutical composition according to claim 4 or claim 5 wherein a therapeutically effective amount of said medicament or pharmaceutical composition is administered topically, locally or systemically to a subject in need thereof.

7. Medicament or pharmaceutical composition according to claim 4 or claim 5 for the treatment or the prevention of a disorder associated with pathological neovascularization in a subject.

8. Medicament or pharmaceutical composition according to claim 7 for inhibiting neovascularization.

9. Medicament or pharmaceutical composition according to claim 7 wherein the disorder associated with pathological neovascularization is selected from the group consisting of cancer and solid tumors; arthritic conditions; neovascular based dermatological conditions; age related macular degeneration; neovascular glaucoma; iridis rubeosis; pterygium.

10. Medicament or pharmaceutical composition according to claim 7 or Claim 9 wherein the disorder is a cancer from the group consisting of prostate cancer; lung cancer; breast cancer; bladder cancer; renal cancer, colon cancer; gastric cancer; pancreatic cancer; ovarian cancer; melanoma; hepatoma; sarcoma and leukemia.

11. Medicament or pharmaceutical composition according to claim 5 to 10 wherein the medicament or the pharmaceutical composition is to be delivered to the eye through topical administration such as eye drops, gels or ointments, through subconjunctival injections or implants, through intravitreal injections or implants, through sub-Tenon's injections or implants, or incorporation in surgical irrigating solutions.

12. Medicament or pharmaceutical composition according to claim 5 to 10, which is to be delivered by oral administration, intravenous, intraarterial, intraperitoneal or transdermal .

13. Medicament or pharmaceutical composition according to claim 7 wherein the fraction of claim 1 or Claim 2 are associated or are in interaction with at least one further anti-angiogenic agent selected from an anti-VEGF, anti-FGF agent, anti-t yr o s ine kinase receptor drugs , interferons (alpha, beta and gamma) , a platelet factor 4 (PF4) , angiostatin, endostatin.

14. Medicament or pharmaceutical composition according to claim 7 wherein the fraction of claim 1 or 2 are associated with a chemotherapeutic compound such as paclitaxel; docetaxel; doxorubicin; cisplatin; bleomycin.

15. Medicament or pharmaceutical compos ition according to claim 7 wherein said medicament or pharmaceutical composition is to be administered to a subject which is an animal selected from the group consisting of a pet and a human patient.